CN · Field Sheet
FIELD SHEET — YOHIMBINE MFI-YOHIMB-20261022-FS
Survey index / YOHIMBINE

Yohimbine.

Pausinystalia johimbe
Pausinystalia alkaloid; stimulant, lipolysis and adverse-event literature.
SEALED MFI-YOHIMB-20261022-FS · RELEASED 2026-10-22
SHEET FINGERPRINTMFI-YOHIMB-20261022-FS
681INCLUDED
1,368EXCLUDED
50DUPLICATE
44NON-TRANSFERABLE
0OUT OF CUTOFF
Survey totalsScroll ↓
2,143records surveyed
681studies
15claims graded
226observations
8,116graph nodes

Claim records

2 shown · bounded preview
RECORD PREVIEW · FIELD RECORD ×2BOUNDED — REAL RELEASED DATA
CLAIM · CLM-5f4cfa9fa5c9019eGRADE VERY_LOW
yohimbine — mood
direction BENEFIT · dose 10 mg; 10 mg/kg; 20 mg; 21.6 mg; 32.4 mg · duration 7 days
Grade basis — weakest-link ceilings
HIGHdesign
LOWdirectness
LOWextraction
LOWconfidence
MODERATEmethodology
MODERATEconsistency
MODERATEnumeric
18bound studies
Bound studies (4 shown of 18)
STU-02f190dd534505de
ANIMAL · ANIMAL · 2023 · RoB INSUFFICIENT_INFORMATION
1 endpoints
STU-0343a3685cd9496b
RCT · HUMAN · 2025 · 7 days · RoB SOME_CONCERNS
1 endpoints
STU-0ee87032cd4a63c0
UNSPECIFIED · HUMAN · 2017 · RoB NOT_ASSESSABLE
2 endpoints
STU-1986235d25abc7a7
UNSPECIFIED · HUMAN · 2019 · RoB NOT_ASSESSABLE
2 endpoints
Quantitative observations
observation 10 mg/kg · validated
observation p=0.005 · validated
observation 234 · validated
Opposition screen
SCREEN · 34 candidates considered · 3 bound as opposing
SYNTHESIS SYN-d1c672daf9b53c — outcome QUALITATIVE_ONLY · BENEFIT ×18 · not_assessed_quantitatively · 18 members
PROVENANCE → epmc:37504003, epmc:39534517, epmc:27841278 · PKG 066833465df51c6c…
CLAIM · CLM-2a7e59d0122f474bGRADE VERY_LOW
yohimbine — cognition
direction BENEFIT · dose 20 mg · duration 14 days
Grade basis — weakest-link ceilings
MODERATEdesign
LOWdirectness
MODERATEextraction
LOWconfidence
MODERATEmethodology
MODERATEconsistency
MODERATEnumeric
11bound studies
Bound studies (4 shown of 11)
STU-0ee87032cd4a63c0
UNSPECIFIED · HUMAN · 2017 · RoB NOT_ASSESSABLE
2 endpoints
STU-207113f6d4bee0bc
IN_VITRO · IN_VITRO · 2022 · RoB INSUFFICIENT_INFORMATION
2 endpoints
STU-4af6ff244935a769
RCT · HUMAN · 2020 · RoB INSUFFICIENT_INFORMATION
4 endpoints
STU-6f258e505594d88a
UNSPECIFIED · HUMAN · 2012 · RoB NOT_ASSESSABLE
2 endpoints
Quantitative observations
observation 19 · validated
observation 44 · validated
observation 20 mg · validated
Opposition screen
SCREEN · 17 candidates considered · 3 bound as opposing
SYNTHESIS SYN-0bfdeabc9f31c6 — outcome QUALITATIVE_ONLY · BENEFIT ×11 · not_assessed_quantitatively · 11 members
PROVENANCE → epmc:27841278, epmc:35945306, epmc:31446157 · PKG 066833465df51c6c…
Bounded preview — representative records only. The full release ships 15 claims and 226 observations.